{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-023644","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.779092+00:00","generated_at":"2026-05-15T21:56:36.870048+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada","bullets":["Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.","Supply price is Emmaus' production cost plus a specified double-digit percentage margin.","Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.","Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).","Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-023644","json":"https://secwatch.observer/filing/0001213900-26-023644.json","markdown":"https://secwatch.observer/filing/0001213900-26-023644.md","text":"https://secwatch.observer/filing/0001213900-26-023644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/0001213900-26-023644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/ea0280016-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:56:36.870048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4dac66637f06494dd75b73626d212e225cf98680","claim":"Emmaus Life Sciences, Inc. entered into Exclusive Supply Agreement with NeoImmuneTech, Inc. (NIT) (effective 2026-03-02).","evidence_excerpt":"n March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390026023644/0001213900-26-023644-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"NeoImmuneTech, Inc. (NIT)"},{"label":"Effective","value":"2026-03-02"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}